Index RUT
P/E -
EPS (ttm) -2.50
Insider Own 11.38%
Shs Outstand 55.59M
Perf Week -8.71%
Market Cap 2.15B
Forward P/E -
EPS next Y -3.09
Insider Trans -11.48%
Shs Float 54.38M
Perf Month 2.04%
Income -154.59M
PEG -
EPS next Q -0.68
Inst Own 99.52%
Short Float 18.22%
Perf Quarter 0.17%
Sales 79.41M
P/S 27.11
EPS this Y -12.17%
Inst Trans 3.66%
Short Ratio 16.59
Perf Half Y 141.67%
Book/sh 11.59
P/B 3.03
EPS next Y -9.32%
ROA -20.86%
Short Interest 9.91M
Perf Year 23.77%
Cash/sh 8.48
P/C 4.14
EPS next 5Y 1.90%
ROE -26.35%
52W Range 9.60 - 45.31
Perf YTD 37.82%
Dividend Est. -
P/FCF -
EPS past 5Y -39.18%
ROI -19.61%
52W High -22.56%
Beta 2.32
Dividend TTM -
Quick Ratio 9.57
Sales past 5Y 241.22%
Gross Margin 94.76%
52W Low 265.52%
ATR (14) 1.95
Dividend Ex-Date -
Current Ratio 9.57
EPS Y/Y TTM 12.88%
Oper. Margin -217.99%
RSI (14) 43.39
Volatility 5.70% 5.17%
Employees 187
Debt/Eq 0.12
Sales Y/Y TTM 70.16%
Profit Margin -194.67%
Recom 1.71
Target Price 50.80
Option/Short Yes / Yes
LT Debt/Eq 0.11
EPS Q/Q 2.46%
Payout -
Rel Volume 1.72
Prev Close 38.36
Sales Surprise -27.75%
EPS Surprise 4.25%
Sales Q/Q 8.67%
Earnings May 02 BMO
Avg Volume 597.13K
Price 35.09
SMA20 -2.13%
SMA50 -7.64%
SMA200 32.55%
Trades
Volume 1,030,013
Change -8.52%
Date
Action
Analyst
Rating Change
Price Target Change
Apr-22-24 Initiated
Oppenheimer
Outperform
$53
Feb-15-24 Initiated
Wolfe Research
Peer Perform
Jan-04-24 Upgrade
JP Morgan
Neutral → Overweight
Jan-03-24 Downgrade
BofA Securities
Buy → Neutral
$45 → $30
Dec-19-23 Downgrade
Wells Fargo
Overweight → Equal Weight
$26
Jun-30-23 Initiated
Truist
Buy
$50
May-05-23 Upgrade
Raymond James
Mkt Perform → Outperform
Dec-06-22 Downgrade
Credit Suisse
Outperform → Neutral
$47 → $32
Nov-08-22 Initiated
Raymond James
Mkt Perform
Aug-15-22 Initiated
Jefferies
Buy
$40
Aug-03-22 Initiated
Goldman
Buy
$40
Jul-20-22 Initiated
SVB Leerink
Mkt Perform
$26
Apr-28-22 Initiated
Credit Suisse
Outperform
$63
Mar-10-22 Initiated
JP Morgan
Neutral
$44
Feb-10-22 Initiated
Wells Fargo
Overweight
$62
Sep-30-21 Initiated
Stifel
Buy
$80
Sep-30-21 Initiated
B. Riley Securities
Neutral
$67
Sep-10-21 Downgrade
BofA Securities
Buy → Neutral
$65 → $80
May-21-21 Initiated
UBS
Buy
$80
Apr-14-21 Initiated
Berenberg
Buy
Show Previous Ratings
Today 10:00AM
May-08-24 07:00AM
May-03-24 12:23PM
09:57AM
09:55AM
08:44AM
Loading…
08:44AM
03:19AM
May-02-24 12:18PM
11:57AM
07:00AM
Apr-25-24 10:02AM
09:20AM
07:00AM
Apr-08-24 07:00AM
Mar-08-24 10:00AM
11:27PM
Loading…
Mar-04-24 11:27PM
Feb-28-24 07:00AM
Feb-23-24 11:59AM
Feb-22-24 11:24PM
(Thomson Reuters StreetEvents)
07:35AM
07:00AM
Feb-21-24 11:52PM
Feb-15-24 10:00AM
07:00AM
Feb-10-24 02:56AM
Jan-31-24 07:00AM
Jan-24-24 12:20AM
Jan-17-24 08:00AM
Jan-09-24 09:17AM
09:15AM
04:03PM
Loading…
Jan-05-24 04:03PM
(Investor's Business Daily)
06:00AM
Jan-04-24 04:01PM
07:00AM
Jan-02-24 07:00AM
Dec-22-23 10:45AM
Dec-18-23 02:58PM
Dec-13-23 07:00AM
Dec-10-23 09:00PM
Dec-08-23 11:13AM
Dec-07-23 07:00AM
Nov-13-23 11:00AM
Nov-07-23 09:05AM
Nov-05-23 02:38PM
Nov-02-23 09:00AM
08:43AM
07:00AM
Nov-01-23 07:00AM
Oct-27-23 07:00AM
Oct-26-23 10:02AM
07:00AM
Oct-19-23 09:35AM
Oct-18-23 09:35AM
Oct-16-23 07:00AM
Oct-04-23 06:23AM
Oct-03-23 04:48PM
Sep-18-23 07:00AM
Aug-28-23 07:00AM
Aug-03-23 08:25AM
07:00AM
Jul-28-23 03:57PM
Jul-27-23 07:00AM
Jul-09-23 09:09AM
Jun-22-23 08:30AM
Jun-14-23 02:30AM
Jun-09-23 06:00PM
03:00AM
Jun-01-23 07:00AM
May-29-23 12:24PM
May-22-23 07:00AM
May-19-23 07:00AM
May-18-23 07:00AM
May-14-23 02:57PM
May-09-23 03:15PM
May-04-23 08:25AM
07:00AM
Apr-19-23 11:11AM
Apr-11-23 07:00AM
Apr-09-23 01:19PM
Mar-09-23 03:00PM
Mar-03-23 11:40AM
Mar-01-23 07:00AM
Feb-24-23 02:53AM
(Thomson Reuters StreetEvents) -5.13%
Feb-23-23 08:25AM
07:00AM
Feb-01-23 07:00AM
Jan-31-23 08:00AM
Jan-30-23 07:26AM
Jan-23-23 04:14AM
Jan-17-23 06:27AM
Jan-10-23 07:00AM
Jan-09-23 12:00PM
Jan-04-23 07:00AM
Jan-03-23 07:00AM
Dec-21-22 04:57PM
Dec-20-22 10:33AM
Dec-15-22 10:27AM
Dec-14-22 04:09PM
(Investor's Business Daily) +14.58%
01:44PM
10:00AM
Kymera Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and development of small molecule therapeutics that degrade disease-causing proteins. The company was founded by Bruce Lee Booth and Nello Mainolfi in September 2015 and is headquartered in Watertown, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Booth Bruce Director Mar 15 '24 Sale 40.46 71,764 2,903,336 806,697 Mar 15 07:23 PM Booth Bruce Director Mar 14 '24 Sale 39.98 55,779 2,229,927 819,151 Mar 15 07:23 PM Booth Bruce Director Mar 13 '24 Sale 42.23 139,255 5,880,415 828,830 Mar 13 07:52 PM Atlas Venture Fund X, L.P. 10% Owner Mar 13 '24 Sale 42.23 115,090 4,859,993 4,676,075 Mar 13 07:53 PM Atlas Venture Fund X, L.P. 10% Owner Mar 13 '24 Sale 42.23 24,165 1,020,422 828,830 Mar 13 07:53 PM Booth Bruce Director Mar 12 '24 Sale 41.98 162,918 6,838,813 852,995 Mar 13 07:52 PM Atlas Venture Fund X, L.P. 10% Owner Mar 12 '24 Sale 41.98 134,647 5,652,072 4,791,165 Mar 13 07:53 PM Atlas Venture Fund X, L.P. 10% Owner Mar 12 '24 Sale 41.98 28,271 1,186,741 852,995 Mar 13 07:53 PM Booth Bruce Director Mar 11 '24 Sale 42.85 51,184 2,193,148 881,266 Mar 13 07:52 PM Atlas Venture Fund X, L.P. 10% Owner Mar 11 '24 Sale 42.85 42,302 1,812,586 4,925,812 Mar 13 07:53 PM Atlas Venture Fund X, L.P. 10% Owner Mar 11 '24 Sale 42.85 8,882 380,562 881,266 Mar 13 07:53 PM Jacobs Bruce N. Chief Financial Officer Mar 04 '24 Sale 41.86 3,934 164,664 142,351 Mar 04 06:12 PM Gollob Jared Chief Medical Officer Mar 04 '24 Sale 41.86 3,344 139,967 95,740 Mar 04 06:21 PM Albers Jeffrey W. Director Feb 21 '24 Option Exercise 10.34 4,385 45,341 4,385 Feb 21 06:46 PM Albers Jeffrey W. Director Feb 21 '24 Sale 39.05 4,385 171,227 0 Feb 21 06:46 PM Albers Jeffrey W. Director Feb 20 '24 Option Exercise 10.34 615 6,359 615 Feb 21 06:46 PM Albers Jeffrey W. Director Feb 20 '24 Sale 39.07 615 24,031 0 Feb 21 06:46 PM Gollob Jared Chief Medical Officer Feb 09 '24 Option Exercise 2.08 46,137 95,965 120,846 Feb 09 07:47 PM Gollob Jared Chief Medical Officer Feb 09 '24 Sale 35.50 46,137 1,638,071 74,709 Feb 09 07:47 PM Albers Jeffrey W. Director Jan 23 '24 Option Exercise 10.34 10,000 103,400 10,000 Jan 23 07:37 PM Albers Jeffrey W. Director Jan 23 '24 Sale 30.05 10,000 300,470 0 Jan 23 07:37 PM Chiniara Ellen Chief Legal Officer Jan 04 '24 Sale 22.58 3,295 74,416 34,205 Jan 05 05:15 PM Mainolfi Nello Chief Executive Officer Jan 02 '24 Option Exercise 2.08 9,000 18,720 615,570 Jan 02 05:43 PM Mainolfi Nello Chief Executive Officer Nov 03 '23 Option Exercise 2.08 20,000 41,600 606,570 Nov 06 06:00 PM BVF PARTNERS L P/IL Director Nov 03 '23 Buy 14.07 197,699 2,781,407 2,656,191 Nov 06 06:07 PM BVF PARTNERS L P/IL Director Nov 02 '23 Buy 11.64 216,406 2,519,918 2,552,306 Nov 06 06:07 PM Mainolfi Nello Chief Executive Officer Aug 08 '23 Option Exercise 2.08 12,000 24,960 586,570 Aug 08 04:30 PM Jacobs Bruce N. Chief Financial Officer Jun 02 '23 Option Exercise 2.08 10,000 20,800 115,035 Jun 02 02:17 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite